Back in February, the Oragenics Inc (NYSE: OGEN) stock had hit its peak but since then it has been a different story.
The stock has tanked by as high as 50% since then and it is fair for investors to perhaps figure out if this could be a buying opportunity. In this regard, it might be useful to go back to development from the end of March. At the time Edward Woo, who is an analyst at Ascendiant Capital, started covering the Oragenics stock and gave it a buy rating.
More importantly, the price target for the stock was pegged at $2.75 a share, which reflects gains of as much as 215% from the closing price on April 1st. It was a significant development considering the hammering the stock had received in the previous weeks. Now it remains to be seen if the report from Ascendiant results in more interest in the stock in the coming days.
Finance and Entertainment Reporter
Richard is a bottle of wine – the older the sweeter. He has already found the sweetest hobby in writing entertainment and finance news for Own Snap. Readers get the updated posts regularly from him searching for real-time news.